Economic burden of psoriasis in the United States a systematic review

JAMA Dermatology

Volumn 151, Issue 6, 2015, Pages 651-658

  Brezinski, Elizabeth A ^a   Dhillon, Jaskaran S ^a   Armstrong, April W ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; CALCIPOTRIOL; CYCLOSPORIN; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE; USTEKINUMAB;

ABSENTEEISM; CEREBROVASCULAR DISEASE; COMORBIDITY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DIABETES MELLITUS; DRUG COST; ECONOMIC ASPECT; ECONOMIC BURDEN; EMOTIONAL STABILITY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MENTAL DISEASE; OBESITY; PERIPHERAL VASCULAR DISEASE; PHOTOTHERAPY; PRIORITY JOURNAL; PRODUCTIVITY; PSORIASIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW; UNITED STATES; ADULT; COST OF ILLNESS; ECONOMICS; HEALTH CARE COSTS; HUMANS; STATISTICS AND NUMERICAL DATA;

ADULT; COST OF ILLNESS; HEALTH CARE COSTS; HUMANS; PSORIASIS; UNITED STATES;

EID: 84931090028     PISSN: 21686068     EISSN: 21686084     Source Type: Journal    
DOI: 10.1001/jamadermatol.2014.3593     Document Type: Review

References (39)

1. Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J AmAcad Dermatol. 2014;70(3):512-516.
2. Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies. J Hypertens. 2013;31(3):433-443.
3. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J AmAcad Dermatol. 2006;55(5):829-835.
4. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk ofmyocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735-1741.
5. Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J AmHeart Assoc. 2013;2(2):e000062. doi:10.1161/JAHA.113.000062.
6. Han C, Lofland JH, Zhao N, Schenkel B. Increased prevalence of psychiatric disorders and health care-associated costs among patients with moderate-to-severe psoriasis. J Drugs Dermatol. 2011;10(8):843-850.
7. Armstrong AW, Harskamp CT, Ledo L, Rogers JH, Armstrong EJ. Coronary artery disease in patients with psoriasis referred for coronary angiography. Am J Cardiol. 2012;109(7):976-980.
8. Armstrong AW, Lin SW, Chambers CJ, Sockolov ME, Chin DL. Psoriasis and hypertension severity: results from a case-control study. PLoS One. 2011;6(3):e18227. doi:10.1371/journal.pone.0018227.
9. Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005;6(6):383-392.
10. Weiss SC, Kimball AB, Liewehr DJ, Blauvelt A, Turner ML, Emanuel EJ. Quantifying the harmful effect of psoriasis on health-related quality of life. J AmAcad Dermatol. 2002;47(4):512-518.
11. Javitz HS, Ward MM, Farber E, Nail L, Vallow SG. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J AmAcad Dermatol. 2002;46(6):850-860.
12. Gunnarsson C, Chen J, Rizzo JA, Ladapo JA, Naim A, Lofland JH. The direct healthcare insurer and out-of-pocket expenditures of psoriasis: evidence from a United States national survey. J Dermatolog Treat. 2012;23(4):240-254.
13. Ebell MH, Siwek J, Weiss BD, et al. Strength of Recommendation Taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. Am FamPhysician. 2004;69(3):548-556.
14. Bureau of Labor Statistics, US Department of Labor. Consumer Price Index. http://www.bls.gov/cpi. Accessed December 8, 2013.
15. Villacorta R, Hay JW, Messali A. Cost effectiveness of moderate to severe psoriasis therapy with etanercept and ustekinumab in the United States. Pharmacoeconomics. 2013;31(9):823-839.
16. Bhutani T, Wong JW, Bebo BF, Armstrong AW. Access to health care in patients with psoriasis and psoriatic arthritis: data from National Psoriasis Foundation survey panels. JAMA Dermatol. 2013;149(6):717-721.
17. Parsi K, Chambers CJ, Armstrong AW. Cost-effectiveness analysis of a patient-centered care model for management of psoriasis. J AmAcad Dermatol. 2012;66(4):563-570.
18. Yu AP, Tang J, Xie J, et al. Economic burden of psoriasis compared to the general population and stratified by disease severity. Curr Med Res Opin. 2009;25(10):2429-2438.
19. Fowler JF, Duh MS, Rovba L, et al. The impact of psoriasis on health care costs and patient work loss. J AmAcad Dermatol. 2008;59(5):772-780.
20. Lin HC, Lucas PT, Feldman SR, Balkrishnan R. Medication use and associated health care outcomes and costs for patientswith psoriasis in the United States. J Dermatolog Treat. 2012;23(3):196-202.
21. Staidle JP, Dabade TS, Feldman SR. A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency. Expert Opin Pharmacother. 2011;12(13):2041-2054.
22. Alora-Palli MB, Brouda I, Green B, Kimball AB. A cost-effectiveness comparison of liquor carbonis distillate solution and calcipotriol cream in the treatment of moderate chronic plaque psoriasis. Arch Dermatol. 2010;146(8):919-922.
23. Beyer V, Wolverton SE. Recent trends in systemic psoriasis treatment costs. Arch Dermatol. 2010;146(1):46-54.
24. Yentzer BA, Yelverton CB, Simpson GL, et al. Paradoxical effects of cost reduction measures in managed care systems for treatment of severe psoriasis. Dermatol Online J. 2009;15(4):1.
25. Ahn CS, Gustafson CJ, Sandoval LF, Davis SA, Feldman SR. Cost effectiveness of biologic therapies for plaque psoriasis. Am J Clin Dermatol. 2013;14(4):315-326.
26. Leonardi C, Sobell JM, Crowley JJ, et al. Efficacy, safety and medication cost implications of adalimumab 40mg weekly dosing in patients with psoriasis with suboptimal response to 40mg every other week dosing: results from an open-label study. Br J Dermatol. 2012;167(3):658-667.
27. Liu Y, Wu EQ, Bensimon AG, et al. Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis. Adv Ther. 2012;29(7):620-634.
28. Bonafede MM, Gandra SR, Watson C, Princic N, Fox KM. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis. Adv Ther. 2012;29(3):234-248.
29. Anis AH, Bansback N, Sizto S, Gupta SR, Willian MK, Feldman SR. Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States. J Dermatolog Treat. 2011;22(2):65-74.
30. Martin S, Feldman SR, Augustin M, Szapary P, Schenkel B. Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis. J Dermatolog Treat. 2011;22(3):138-143.
31. Wu EQ, Feldman SR, Chen L, et al. Utilization pattern of etanercept and its cost implications in moderate to severe psoriasis in a managed care population. Curr Med Res Opin. 2008;24(12):3493-3501.
32. Nelson AA, Pearce DJ, Fleischer AB Jr, Balkrishnan R, Feldman SR. Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period. J Am Acad Dermatol. 2008;58(1):125-135.
33. DelfinoMJr, Holt EW, Taylor CR, Wittenberg E, Qureshi AA. Willingness-to-pay stated preferences for 8 health-related quality-of-life domains in psoriasis: a pilot study. J AmAcad Dermatol. 2008;59(3):439-447.
34. Kimball AB, Guérin A, Tsaneva M, et al. Economic burden of comorbidities in patients with psoriasis is substantial. J Eur Acad Dermatol Venereol. 2011;25(2):157-163.
35. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9(2):136-139.
36. Schmitt JM, Ford DE. Work limitations and productivity loss are associatedwith health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology. 2006;213(2):102-110.
37. Lewin Group. The Burden of Skin Diseases: 2005. Falls Church, VA: Lewin Group, for the Society of Investigative Dermatology and the American Academy of Dermatology Association; 2005.
38. Crown WH, Bresnahan BW, Orsini LS, Kennedy S, Leonardi C. The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US. Curr Med Res Opin. 2004;20(12):1929-1936.
39. Puig L. Treatment of moderate to severe plaque psoriasis with biologics: analysis of the additional cost of temporary dose escalation vs switch to another biologic after failure of maintenance therapy. Actas Dermosifiliogr. 2014;105(4):401-412.